CA2146192C - Polyionic insoluble hydrogels comprising xanthan - Google Patents
Polyionic insoluble hydrogels comprising xanthanInfo
- Publication number
- CA2146192C CA2146192C CA002146192A CA2146192A CA2146192C CA 2146192 C CA2146192 C CA 2146192C CA 002146192 A CA002146192 A CA 002146192A CA 2146192 A CA2146192 A CA 2146192A CA 2146192 C CA2146192 C CA 2146192C
- Authority
- CA
- Canada
- Prior art keywords
- chitosan
- xanthan
- hydrogels
- hydrogel
- xylanase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 92
- 229920001285 xanthan gum Polymers 0.000 title claims abstract description 77
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 229920000831 ionic polymer Polymers 0.000 title description 8
- 229920001661 Chitosan Polymers 0.000 claims abstract description 112
- 102000004190 Enzymes Human genes 0.000 claims abstract description 46
- 108090000790 Enzymes Proteins 0.000 claims abstract description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 claims abstract description 24
- 239000004365 Protease Substances 0.000 claims abstract description 24
- 108091005804 Peptidases Proteins 0.000 claims abstract description 22
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 20
- 229940088598 enzyme Drugs 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 20
- 239000004367 Lipase Substances 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 102000004882 Lipase Human genes 0.000 claims description 5
- 108090001060 Lipase Proteins 0.000 claims description 5
- 235000019421 lipase Nutrition 0.000 claims description 5
- -1 orthomycin Natural products 0.000 claims description 4
- 238000005538 encapsulation Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 4
- 229940059442 hemicellulase Drugs 0.000 claims description 3
- 108010002430 hemicellulase Proteins 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- UXRHCHSWRDOIED-UHFFFAOYSA-N Adenomycin Natural products OC1C(OS(O)(=O)=O)C(OC(=O)C(CO)N)C(OCC2C(C(O)C(O2)N2C3=NC=NC(N)=C3N=C2)O)C(O)C1OC1OC(CO)C(O)C(O)C1N UXRHCHSWRDOIED-UHFFFAOYSA-N 0.000 claims description 2
- 108010006654 Bleomycin Proteins 0.000 claims description 2
- 229930186147 Cephalosporin Natural products 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 229930193140 Neomycin Natural products 0.000 claims description 2
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims description 2
- 108010059993 Vancomycin Proteins 0.000 claims description 2
- UXRHCHSWRDOIED-QVEOBRIHSA-N [(1r,2s,3s,4s,5r,6r)-4-[(2r,3s,4r,5s,6s)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,5-dihydroxy-6-sulfooxycyclohexyl] (2s)-2-amino-3-hydroxypropanoate Chemical compound O([C@H]1[C@@H](O)[C@H](OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)[C@H]([C@@H]([C@@H]1O)OS(O)(=O)=O)OC(=O)[C@H](CO)N)[C@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1N UXRHCHSWRDOIED-QVEOBRIHSA-N 0.000 claims description 2
- 229960001561 bleomycin Drugs 0.000 claims description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 2
- 229940124587 cephalosporin Drugs 0.000 claims description 2
- 150000001780 cephalosporins Chemical class 0.000 claims description 2
- 229960005091 chloramphenicol Drugs 0.000 claims description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960000975 daunorubicin Drugs 0.000 claims description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims description 2
- 229960000318 kanamycin Drugs 0.000 claims description 2
- 229930027917 kanamycin Natural products 0.000 claims description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 2
- 229930182823 kanamycin A Natural products 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims description 2
- 229960003171 plicamycin Drugs 0.000 claims description 2
- 229960001404 quinidine Drugs 0.000 claims description 2
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001544 sulfathiazole Drugs 0.000 claims description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 2
- 229960003165 vancomycin Drugs 0.000 claims description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- 229940088623 biologically active substance Drugs 0.000 claims 2
- 239000004100 Oxytetracycline Substances 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 229960000625 oxytetracycline Drugs 0.000 claims 1
- 235000019366 oxytetracycline Nutrition 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 229930188428 trichomycin Natural products 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 239000000499 gel Substances 0.000 abstract description 25
- 238000010668 complexation reaction Methods 0.000 abstract description 22
- 230000021736 acetylation Effects 0.000 abstract description 19
- 238000006640 acetylation reaction Methods 0.000 abstract description 19
- 238000000034 method Methods 0.000 abstract description 13
- 238000009792 diffusion process Methods 0.000 abstract description 9
- 230000002378 acidificating effect Effects 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000007935 neutral effect Effects 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000012620 biological material Substances 0.000 abstract description 2
- 238000013268 sustained release Methods 0.000 abstract description 2
- 239000012730 sustained-release form Substances 0.000 abstract description 2
- 229910002056 binary alloy Inorganic materials 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000004005 microsphere Substances 0.000 description 16
- 239000000758 substrate Substances 0.000 description 15
- 230000008961 swelling Effects 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 229920000447 polyanionic polymer Polymers 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 9
- 239000008351 acetate buffer Substances 0.000 description 8
- 230000009102 absorption Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229920000867 polyelectrolyte Polymers 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 108010093096 Immobilized Enzymes Proteins 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000003822 epoxy resin Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 229920000647 polyepoxide Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000008364 bulk solution Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229960000292 pectin Drugs 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 229920001221 xylan Polymers 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000223261 Trichoderma viride Species 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- VQQSDVBOXQHCHU-SKPOXZENSA-N antelmycin Chemical compound O[C@@H]1[C@@H](N)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)[C@@H]1[C@@H](N)[C@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 VQQSDVBOXQHCHU-SKPOXZENSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- KUIXZSYWBHSYCN-UHFFFAOYSA-L remazol brilliant blue r Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=C2C(=O)C3=CC=CC=C3C(=O)C2=C1NC1=CC=CC(S(=O)(=O)CCOS([O-])(=O)=O)=C1 KUIXZSYWBHSYCN-UHFFFAOYSA-L 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
A method for the preparation of insoluble hydrogels from the complexation of polycations and xanthan is reported. Stable hydrogels capable of retaining between 65 and 95% weight water were prepared particularly with chitosan and xanthan. The water retention and properties of the hydrogels were studied as a function of the degree of acetylation of chitosan and the ratio chitosan/xanthan used in the preparation of the gel.
The chitosan-xanthan complex was used to immobilize biological material. Hydrogels containing enzymes (for example endo-1,4-.beta.-xylanase and protease) either as single enzymes or as a binary system have been prepared.
Immobilization varied between 85 and 98%. The immobilized xylanase activity was significantly greater with respect to the free enzyme while the binary enzyme system promoted protease activity. Other hydrogels prepared with polybasic drugs complexed to xanthan with or without chitosan have been prepared. These complexes slowly dissociate in acidic media and provide for sustained release of compounds in near neutral pHs.
Gels containing chitosan are stable in all physiological pHs and the immobilized molecules are released therefrom by diffusion.
The chitosan-xanthan complex was used to immobilize biological material. Hydrogels containing enzymes (for example endo-1,4-.beta.-xylanase and protease) either as single enzymes or as a binary system have been prepared.
Immobilization varied between 85 and 98%. The immobilized xylanase activity was significantly greater with respect to the free enzyme while the binary enzyme system promoted protease activity. Other hydrogels prepared with polybasic drugs complexed to xanthan with or without chitosan have been prepared. These complexes slowly dissociate in acidic media and provide for sustained release of compounds in near neutral pHs.
Gels containing chitosan are stable in all physiological pHs and the immobilized molecules are released therefrom by diffusion.
Description
~ 2l46l92 TITLB OF THE lNV~ ON
POLYIONIC INSOLUBLE HYDROGELS COMPRISING XANTHAN
FIELD OF THE lNV~. 1 lON
This invention relates to hydrogels made of polyionic complexed molecules, particularly to hydrogels for use in slow release formulations of blologically active molecules.
R~R~OUND OF THB lNVL~ ON
Hydrogels can be classified into two broad categories: reversible and irreversible. The former are characterized by significant changes in the rheological properties as a function of temperature, ionic concentration, and dilution. Irreversible hydrogels are soluble in water, as well as in other solvents, over a wide range of temperatures and dilutions. Due to their solubility profiles, irreversible hydrogels have multiple applications in food, cosmetics, medicine and biotechnology [1-5]. The preparation of hydrogels can be achieved by a variety of methods: reticulation of linear polymers; grafting of synthetic polymers onto naturally occurring macromolecules; chelation of polycations; and complexation between polyanions and polycations [6-8].
- ' 21461~2 Chitosan, the deacetylated form of chitin (N-acetyl glucosamide), has polycationic properties and forms, with polyanions, water insoluble hydrogels [9-14]. These have been successfully used as a support material for the immobilization of enzymes and cells [15-20] and for controlled drug release [20-24]. The immobilization of enzymes using organic and inorganic matrices has been widely studied [25-30] and a variety of immobilization methods such as chemical reaction, microencapsulation, and adsorption on various surfaces have been used [31-34]. Our attention has focused on enzyme immobilization using hydrogels because their hydrophilicity allows, in principle, for the creation of microsystems favourable for enzymatic activity. Complexes of cationic polymers have been prepared with different polyanions like synthetic polyanions (polyacrylic, polymethacrylic acids and polyvinyl alcohol sulfate [52-54]; natural polyanions (alginate, heparin, carrageenan, pectin, glycosaminoglycanes [55-60]; cellulosic derivatives (carboxymethylcellulose and oxydized cellulose [61-62]).
Complexes of natural polyions such as chitosan, carboxymethylcellulose and alginic acid are already known [35,37,38], and enzymes and other bioactive compounds have been immobilized or lodged therein [39-41]. All the hydrogels known in the art have however a capacity of CA 02146192 1997-0~-0~
encapsulation oi biological products (medication, enzymes and cells) which retention yield is very low, v~rying from 1 to 8%. In all these cases, the enzymes conserve only 50 ~ of their initial activity. Therefore, there is clearly a need ~or polyionic hydrogels showing a more per~orming retention yield as well as an improved activity for the retained enzymes~.
SUMMARY OF THE lNv~llON
It is an object of the presen~ invention to provide hydrogels having high retention yields of biological products. Not only do the hydrogels of this invention have a very good retention yield, they also preserve and/or enhance the activity of complex molecules like proteins and enzymes immobilized therein. These hydrogels comprise a polycationic molecule like chitosan or polybasic drugs as a natural polycation complexed with xanthan as a po]yanion.
In a preferred embodiement, the polycationLc molecule is chitosan. Hydrogel composition depends on the acetylation deg:ree of the chitosan which will determine the charges of this compound and its ability to complex to xanthan. The swelling capacity of the hydrog~ls depends on the molecular weight of the chitosan component, its CA 02146192 1997-0~-0~
acetylation degree and also on the surface area of the prepared products, being microspheres, spheres and films/sponges.
In a prer~e3-red embodiement 03~ the present invention, the biological products encapsulated and immobilized in chitosan/xanthan hydrogels are enzymes. For all enzymes tested, as sing]e or combined enzymes, the retention yield varies ~rom 80 to 98~. The enzymes are included in proportions that are up to 25~ of the hydrogel mass.
These enzymes a-îe slowly -Leleased by diLLusi~ln from che hydrogels. When compared to the activity of the free enzymes, the activity of encapsulated enzymes may be improved by 2 or 3 fold.
In another embodiement of the invention, a large panel 03' neutral drugs have been encapsulated in chitosan/xanthan hydrogels. These neutral drugs have been shown to be released from the gels following zero order kinetics.
In another embodiement of the invention, polybasic drugs have been complexed with xanthan with or without chitosan. This system releases the drug at neutral and acidic pHs also following a zero order kinetics.
The advanrages of the hydrogels of the present invention are conferred by the preservati~n of the biological activities of the immobilized molecules. Also, 21~C192 the hydrogels containing chitosan are stable in acidic pHs, a characteristic very useful for per os administration of medications. The hydrogels will desintegrate only in basic solutions which pH is equivalent to the pH of a 10~ NaOH solution. The hygrogels are therefore stable in all encountered physiological pHs. When polybasic drugs are directly complexed with xanthan, the former are slowly dissociated from the latter in acidic conditions and the speed of dissociation decreases as the pH increases. A sustained release is achieved at pH of 6 to about 8, which makes the compositions useful for external use (applied to the skin pH 6.5) as well as for internal use.
DESCRIPTION OF THB lNVlSL~ 1~ lON
Hydrogels made of polycationic and polyanionic compounds have been the subject of many studies. A study conducted by Kim and Rha [37] has shown that hydrogels might be good substrates for immobilized cells. The results obtained with regard to improved cell adhesion and growth cannot however be applied to predict the improvement of immobilization and activity of molecules like enzymes. The conformation of enzymes is rarely predictable and the enzymes are most often very capricious towards environmental conditions that will determine their CA 02146192 1997-0~-0~
conformation and their degree of activity. Therefore, even though the encapsulation o~ cells has been made with success, encapsulation of enzymes has not shown a great improvement with regard to the retention of enzymes in hydrogels and most importantly, the preservation of the biological activity of such encapsulated enzymes.
The use of natural polyanionic substances in the formation of complexes with polycations is already known.
Indeed, alginates, heparin, carrageenan, pectin, glycosaminoglycans have already been tried. However, the retention capacity of complex molecules like enzymes in these hydrogels is far from excellent (between 1 and 8~).
Moreover, the enzymes immobilized in these hydr~gels loose about 50~ of their activity. Xanthan ii3 a known polyanion. Although this polysaccharide produced by Xanthomonas campestris might be on first sight another natural polyanion among others, its complexation with a polycation like chitosane has revealed, in accordance with the present invention suprisingly good properties with regard to the retention yield of enzymes and the preservation o:r enhancement of the activity of such immobilized enzymes.
In the present invention, other polycations might be used in lieu of chitosane. For example, a complex made of xanthan and polybasic drugs have provided good insoluble hydrogels having high retention capacities and showing stability in acidic media.
A full description of this invention is made hereinbelow by way of examples and figures which purpose is to illustrate the invention rather than to limit its scope.
BRIEF DESCRIPTION OF THE FIGURES:
Figure 1 shows the complexation yield of chitosan as a function of the chitosan/xanthan ratio for three samples of chitosan having different acetylation degrees (10, 28 and 34~). pH of the solution: 6.3.
Figure 2 shows the complexation yield of chitosan as a finction of the quantity of chitosan in a 123 mL
solution with 0.4 g xanthan. pH of the solution: 6.3.
Figures 3a, b and c show the swelling capacity (Q) as a function of time at different pHs: 3.6, 5.0 and 8Ø
The chitosan has an acetylation degree of 10~.
Figure 4 shows the relative xylanase activity when immobilized in hydrogels alone or co-immobilized in the same with protease (PR) or lipase (LI) as a function of the concentration of xylanase in the solution of xanthan introduced into the solution of chitosan.
21~6192 MATT~T~T.'.~: AND hh~ VS
Xanthan (X) (Aldrich, batch no. 08403HY) was purified by dissolution in water (1 wt~ of xanthan) and precipitation with isopropyl alcohol. Four dissolution-precipitation cycles were used to lower the N
content from 0.7 wt~ (initial xanthan) to 0.15 wt~ in the purified xanthan. The latter was dissolved again in water (1 wt~), precipitated with ethyl alcohol (50/50 v/v), filtered and rinsed with ethyl alcohol/water mixtures (varying from 2/1 to 1/2 by volume). The resultant xanthan was again dissolved in water (1.5 wt%) and lyophilized. The N content was 0.09 wt%. Solutions of this xanthan were prepared by adding 3.5, 5.45 and 6.5 g to 1000 mL of water for preparing microspheres, spheres and films, respectively.
Chitosan (CH) were dissolved in 300 mL of 0.1 N HCl.
- The solution neutralized with 0.1 N NaOH, and distilled water was added for a total volume of 1000 mL at pH = 6.3.
Two chitosan samples with degrees of acetylation (DA) of 28~ and 10~ were derived from the Sigma chitosan (DA =
34~; batch no. C-0792) using alkaline hydrolysis (30 NaOH) at room temperature for 1 h and 2.5 h, respectively.
'_ 2146192 g Example 1 The hydrogel was prepared by mixing 61.5 mL of the chitosan solution with 61.5 mL of the xanthan solution.
Agitation was conducted for 10 min at room temperature and the hydrogel formed was separated out by centrifugation at 3000 rpm. The hydrogel was washed repeatedly with water to remove the free chitosan and xanthan which were monitored for in the wash water by HPLC (xanthan and chitosan) and by titration of the amine groups on chitosan.
Example 2 The chitosan (CH/X) hydrogels were also prepared as spheres in the following way: 30 mL of the chitosan solution were added dropwise, with a syringe, into 20 mL
of the xanthan solution previously degassed. Spheres formed under mild agitation at room temperature. The spheres were collected and washed with an acetate buffer solution (0.2 M, pH = 3.6) to eliminate the excess free chitosan. The spheres were then rinsed with water. The spheres were kept in an acetate buffer, 0.25 M, at pH =
3.6.
Example 3 Solutions of chitosan (having different degrees of acetylation (10, 28 and 34~) were prepared as follows: 6.5 ~ 2146192 g chitosan were dissolved in 1~ acetic acid and precipitated with 10~ NaOH. The precipitated chitosane was successively washed with water (4-5 L), alcohol/water (50/50 v/v) alcohol (95~). The purified chitosane was then dried by lyophilization. Different solutions of chitosan were made as follows:
- For microspheres, 3.5 g chitosane were dissolved in 100 mL HCl lN, neutralized with NaOH lN till a pH= 3.8 is obtained, and then the volume of the solution was made one liter with water. The electrolyte concentration was 0.09 M NaCl;
For spheres (1-2 mm), 5.45 g chitosan were dissolved in 300 mL HCl lN, neutralizes with NaOH lN till a pH= 5.5 was obtained, and the volume of the solution completed to one liter with water. The electrolyte concentration 0.18 M NaCl;
For films, 6.5 g chitosan were dissolved in 300 mL
HCl lN, neutralized with NaOH lN till a pH=6.5 was obtained. After volume completion to one liter with water, the electrolyte concentration was 1.8 M NaCl.
Solutions of chitosan and xylan are degazed.
For preparing the microspheres, to 20 mL of a 0.35~
xanthan solution placed in a reactor with an agitating system is added 20 mL of a 0.35~ chitosan solution with the aid of a seringe of a diameter of .1 mm. The diameter '~- ' 2l~6l92 of the microspheres depend on the speed of agitation, the seringe diameter and the speed of introduction of chitosan in the xanthan solution. We have tested a speed of agitation of 500 rev./min. and a speed of introduction of chitosan of 0.5-2 mL/min. After the addition of chitosane is completed, the mixture is kept under agitation for 30 minutes. The reaction mixture is then diluted with 200 mL
acetate buffer 0.1 M pH=5.6. The microspheres are are decanted and washed with 500 mL of the same buffer until no free xanthan or chitosan is left (verified by isopropyl alcohol precipitation for xanthan and by NaOH 10 N
precipitation for chitosan). The microspheres are kept in in the same buffer for further use.
For preparing the spheres, a 20 mL chitosan solution (0.545%) is introduced in a reactor, and a 20 mL xanthan solution of varying concentration is added at a speed of introduction of 0.5 mL/min with the aid of a 0.2-0.5 mm diameter seringe under low speed of agitation to avoid aggregation of the spheres. The preparation is further processed like for the microspheres. The spheres have a diameter varying from 1.5 to 2 mm diameter.
For preparing films, 12 mL of a xanthan solution (0.65%) was poured into a 100 mm Petri plate. On a perfectly plane surface, the solution was allowed to rest for at one hour to obtain a layer of homogenous thickness.
21g6192 20 mL of a chitosan solution was added with a seringe, taking care for not disturbing the xanthan layer. These two phases are allowed to stay for two hours. The formed film is taken from the plate walls. The reaction further proceeds at room temperature for at least four days. The solution formed at the top of the film is withdrawn with a seringe, and the film is washed in the following successive solutions:
-10 mL acetate buffer 0.1 M, pH 5.3 (3 X 30 minutes);
-10 mL CaCl2 1~ (2 X 30 minutes);
-10 mL NaCl 2~ (4 X 30 minutes); and -25 mL water (5 X 30 minutes).
Sponges can be also made following substantially the same procedure as for preparing films, but changing the drying procedures for enhancing the size of the pores formed in the films.
The reaction yields were determined using the following relationship:
yield = (weight of dry gel) X 100 (weight of chitosan) + (weight of xanthan) 21~6I92 The degree of swelling, ~, of the hydrogels was determined by weighing the dry hydrogels before and after immersion in the acetate buffer at 2 min intervals, and was defined as:
a = (weight of hydrated gel) - (weight of dry gel) X 100 (weight of dry gel) By plotting ~ versus time of immersion the saturation value was determined when a reaches a plateau, which corresponded to ~m~. From this plot, the swelling capacity, Q, was determined:
Q = [weight of gel at maximum swelling]
[weight of dry gel]
The water content, W, of the hydrogel at equilibrium was determined by:
(weight of gel at maximum swelling) -W = . (weight of dry gel) X 100 (welght of gel at maximum swelling) The degree of acetylation, DA, of chitosan was determined from elemental N analysis data using the following relationship:
DA =[(8.695 ~ %~ X 100 where 8.695 is the %N of a completely deacetylated chitosan, and 1.799 is the difference between 8.695 and 6.896. This latter value is the N~ in completely acetylated chitin.
The FTIR spectra were carried out using a Nicolet (model 5DXB) spectrometer operated in the 400-4600 cm~
region, and 400 scans were collected at a resolution of 4 cm~l. The samples were prepared by mixing KBr with either chitosan, xanthan or the polygel. Typically, 3.5 mg of organic material were mixed with 350 mg of KBr. The mixture was well blended and finely ground for 1 min after which a pellet was prepared at a pressure of 1.0 MPa. The pellet was dried under vacuum, at room temperature, for a period of 24 h in the presence of P2O5.
The hydrogel samples to be used for the transmission and scanning electron microscopic observations (TEM, SEM) were stabilized with glutaraldehyde (1 wt%) in a 0.1 M
phosphate buffer at pH = 7.2 for 15 to 60 min at 4~C. Then these samples were washed repeatedly with a 0.1 M
phosphate buffer solution. The samples were then post-fixed in 1% osmium tetroxide (OSO4) in a 0.1 M
21~6192 phosphate buffer at pH = 7.2 for 24 h at 4~C. After repeated washings with the buffer solution, the samples were dehydrated sequentially with ethanol solutions with increasing ethanol concentration (30, 50, 70, 90, 95, 100 vol~).
For SEM, the ethanol impregnated gel samples were totally dried by the critical point drying method (CPD) using CO2. The dried samples were then fixed on aluminium sample holders using a silver based adhesive. The samples were made conductive by sputter coating (Anatech Ltd., model Hummer VI) with a 15 nm layer of Au/Pd. A JEOL
JSM-840A scanning electron microscope operated under an accelerated voltage of 15 or 20 kV was used for the observations.
For TEM, the samples were dehydrated with 100~
ethanol, placed into liquid propylene oxide for a few minutes and then into a 1:1 mixture of propylene oxide and epoxy resin (EPON) overnight. After that, the samples were transferred into pure epoxy resin and placed in an oven at 60~C for 48 h to polymerize. After polymerization, ultra-thin sections, 600 A in thickness, were made and stained with uranyl acetate and lead citrate. The thin sections were e~m;ned under a Philips EM 300 transmission electron microscope at an accelerating voltage of 60 kV.
_ ' 214619~
The immobilization of the enzymes was carried out as follows: to an a~ueous solution of xanthan (0.65 wt~), the enzymes [endo-1,4-~-xylanase from Trichoderma viride, 2.5 U/mg (Fluka); protease type XIX fungal from Aspergillus 5 sojae, 0.4 U/mg (Sigma); or enzyme mixtures at various ratios] were added at concentrations varying between 0.5 and 1.8 wt~. The solution was agitated for 15 min at 15~C
and introduced dropwise, with a syringe, into the chitosan solution. The latter was adjusted to pH = 6.3 for the protease preparations and to pH = 4.3 for the xylanase preparations alone. The microspheres formed were agitated for 15 minutes at room temperature (20-22~C) and washed with an acetate buffer (0.5 M, pH = 5.3). They were then kept at 5~C in an acetate buffer (0.05 M, pH = 5.3).
The enzymatic activity of the immobilized xylanase and protease was determined using the following established methods [42-43].
Protease As~ay A 2~ hemoglobin solution was prepared by dissolving (with gentle stirring) 5 g of hemoglobin substrate powder (SIGMA) in a solution of 80 g of urea in 80 mL of water.
After incubation at 37~C for 60 min, 50 mL of 0.25 M
buffer were added. The pH was adjusted to 7.2 and then the solution was diluted to 250 mL with water. When casein or other protein was used, the substrate solution could be prepared without urea. All the solutions were equilibrated at 25~C before use. The assay was started by adding 5 mL
of temperature-equilibrated substrate solution to 0.02 g of immobilized protease and mixed thoroughly but gently to prevent frothing. The mixture was incubated at the desired temperature for a fixed period of time not exceeding 10 min. Multiple assays were performed by adding substrate to successive tubes in 30 sec intervals. The reactions were terminated in the same sequence. At the end of the incubation period, the reaction was terminated by adding 10 mL of 5~ trichloroacetic acid to the assay mixture. A
blank was prepared by combining the trichloroacetic acid with the immobilized enzyme and then substrate was added.
The assay mixture and blank were allowed to stand for 30 min. The precipitate material was removed by centrifugation. The absorbance of the supernatant was measured at 280 nm, with reference to the blank. One unit of enzyme activity is defined as the amount of enzyme required to cause a unit increase in absorbance at 280 nm across a 1 cm path length, under the conditions of the assay. The enzymatic activity was expressed in activity units per unit weight of the dry microsphere.
21~6192 Xylanase Aseay A Remazol Brilliant Blue R-Xylan (RBB-xylan) solution in 0.05 M acetate buffer, pH 5.4, 5.75 mg/mL was used.
Immobilized enzyme (0.02 g) was mixed with 0.5 mL of preheated (30~C) RBB-xylan (5.75 mg/mL) solution and incubated at 30~C. The reaction was terminated by the addition of 1 mL of ethanol to precipitate the unhydrolyzed RBB-xylan and the high molecular weight fragments. After standing for 30 min at room temperature (thermal equilibration of samples), the precipitated substrate was recovered by centrifugation at 2000 g for 1.5 min. The absorbance of supernatant was measured at 595 nm against the respective substrate blank. The enzymatic activity was expressed in activity units per unit weight of the dry microsphere. The effective diffusion coefficient of RBB-xylan in the hydrogel was calculated from the changes in the solution concentration determined by absorption at 595 nm.
Other assays using cells, drugs and enzymes:
The behavior of other immobilized and co-immobilized enzymes (lipase and hemicellulase with or without xylanase) has also been verified. Furthermore, chitosan/xanthan hydrogels incorporating neutral drugs have been made. TYpical neutral drugs include CA 02146192 1997-0~-0~
.
cephalosporin, t:etracyclin, oxytetracyclin, sulfathiazole, metronidazole, chloramphenicol, daunorubicin, ampicilin, penicilin, eryt;hromycin, quinidine, alacacinomycin and mithramycin. The same hydrogels may also be used as a support for eucaryotic and procaryotic cells. Gels can also be made by substituting a part or the totality of the chitosan by other polycations. Examples of polycations are polybasic drugs like gentamycin, bleomycin, anthelmycin, enzomycin A, vancomycin, t:richomycin, adenomycin, orthomycin, neomycin, kanamycin and sisomycin.
RESULTS AND DIS~CUSSION
The complexation reaction between the polyions leads to structural changes in both xanthan and chitosan polymers. A water insoluble hydrogel was formed by blocking the hydrophillic functions (R-COOH in case of polyanions and R'-NH2 for the polycations) and by the interaction between the macromolecular chains. The latter effect createcl an "ionic" reticular net:work that immobilized the polymers. The hydrogel formed incorporated a significant amount of water and was ,-apable of stabilizing biological products in the matrix.
We studied the complexation reaction between xanthan and chitosan by determining the yields and the structure of the complexes formed as well as th,- swelling 21~6192 capacities. Three chitosan samples with degrees of acetylation (DA) of 10, 28 and 34~ were used. Figures 1 and 2 show the efficiency (yield) of the complexation reaction as a function of the xanthan/chitosan ratio and the mass concentration of chitosan, respectively. The complexation efficiency was as high as 90% of the available chitosan. The less deacetylated chitosan (DA =
34%) formed a stable hydrogel with the highest chitosan/xanthan ratio. In fact, the lower the DA the greater amounts of xanthan were needed to form a stable hydrogel.
For the same degree of acetylation (DA= 10~), the yield of formation of spheres, microspheres and films depends on the chitosan/xanthan ratio, as shown in Table 1.
Table 1. Variation in the complexation yield as a function of the CH/X ratio for various forms of hyd,G~el~
Yield of complexation (~) Ratio CH/X
(g/g) Microspheres Spheres Films 0.2 89 90 98 0.5 98 87 93 0.7 85 83 90 0.9 76 81 73 1.2 58 69 53 The chitosan content of the hydrogel (spheres) was determined from the N content which depended upon the degree of chitosan acetylation and, to a lesser extent, on the CHjX ratio used in the complexation reaction, as shown in Table 2.
Table 2. Composition of the hydrogels a~ a function of the degree of acetylation Ratio N Content Composition CH/X' of Sample (g/g) Hydrogel Chitosan Xanthan (%) (%) (%) 1 0.4923.30 38.861.2 2 0.5073.38 39.760.3 3 0.5403.41 40.159.9 4 0.5703.52 41.458.6 0.5552.04 24.975.1 6 0.5802.28 27.872.2 7 0.6422.31 28.271.8 8 0.7072.40 29.370.7 9 0.5921.96 24.375.7 0.6282.10 26.074.0 11 0.7202.25 27.872.2 12 0.8072.38 29.570.5 Sample % N in Chito~an DA (%) b 1-4 8.51 10 5-8 8.19 28 9-12 8.08 34 aCH/X = chitosan to xanthan.
bDA = degree of acetylation.
The results indicate that a higher DA lowered the chitosan content of the complex due to a decrease in the free amine available for complexation. The chitosan content in the hydrogel increased with the CH/X ratio in the reaction.
The method of preparation of the hydrogels (microspheres, spheres and films) was determinant in their composition, as shown in Table 3.
Table 3.
Composition (~) Hydrogel Types Chitosan Xanthan 10Microspheres 46.1 53.9 Spheres 39.7 60.3 Films 26.8 73.2 Initial CH/X = 0.5 g/g; DA chitosan = 10~; Mn chitosan =
691,390. The pH value is specific to each type of preparation (See Materials and Methods) We studied the influence of the pH of the chitosan solution on the yield of complexation with xanthan. The results are shown in Table 4.
CA 02146192 1997-0~-0~
.
Table 4. Influence of the pH of the chil;osa.n solution (0.65 wt%) on the complexation ~ith xanthan pH Xanthan Comp~e~a-tion (%) 1.~; 21 2.~; 36 3.5 56 4.5 60 5.5 78 6.3 9~
Chitosan to xanthan ratio (CH/X) = 0.65 g/g.
M chitosan = 691,390 determined by measuring the intrinsic viscosity.
[~] = 1.81 x 10-3 M093; the value 0.93 being determined in 0.1 M acetic ac:id/0.2 M NaCl solution at 25~C [36].
Poor complexation at low pHs was observed due to strong protonation of t:he amine groups which impeded t:he reaction with the carboxylic groups present in the xanthan. Similar results have been reported for the complexation of chitosan with CMC and alginic acid [37-38].
The molecular weight of chitosan ha.d a strong influence on the properties of the hydrogel, particularly the water rete:ntion capacity and the solubility under basic conditions. The effect of molecular weight on water retention was st,udied using four samples of ch.itosan with similar degrees of acetylation but molecular weights varying from 69:L,930 to 122,350. The results a:re shown in Table 5.
CA 02l46l92 l997-0~-0 Table 5. Influexlce of the molecular weight of ~hitosan on the absorption ~f water by the chi.tosan-xanthan hydrogel Chitosana DAb of Co~Lplexation ~ c M~ Chitosan (%) Yield (~) (%) 5691,930 28.0 98.9 560 452 r 875 27.9 97.2 805 191,325 28.2 84.5 992 122 r 350 28.8 81.3 1050 a Determined by measuring the intrinsic viscosity [~] =
1.81 x 10-3 M0-93 in 0.1 M acetic acid/O. 2 M NaCl ,301ution at 25~C [36] .
bDA = degree of acetylation.
C~max = maximum hydrogel swelling.
pH = 5.0: buffer acetate 0. 2 M.
15 The decomposition of the chitosan-xanthan hydrogel in basic media depended on the pH and the ionic concentration of the buffer solution. In the pH range between 7.0 and 9.2~ the hydrogel is stable and independent of- the ionic concentration. At pH > 9. 2 ~ decomposition of the complex 20 begins at 2 M concentration. In a 10 wt~ NaOH solution the complex broke down completely.
The FTIR spectra of the hydrogels have the characteristic absorption bands of chitosan and xanthan (data not shown). The chitosan spectrum has the following 25 characteristic absorption bands: the amide I band (C=O
stretching vibration at 1653 cm~l) and amide I:[ band (N-H
bending and C-N stretching). The spectrum shows that the material has a low degree of acetylation at 1599 cm~1 and CA 02146192 1997-0~-0~
shoulder at 1563 cm~1. The characteristic bands :or xanthan are due to C=O stretching of. the ester groups a.t 1730 cm~
and of the H-bo:nded or ionized carboxylic groups at 1650 cm~1 and lower f'requencies. Complexation did not affect the behaviour of' the ester group which showed clS expected a less intense absorption around 1730 cm~1. Al]. the other C=O absorptions from carboxylic groups mentioned above collapse after complexation to form a single large band centered at 1620 cm~1. The amide II is seen as a shoulder.
We noted that the 1620 cm~1 band in the chitosan-xanthan gel is stronger than that of xanthan due to the conjugation between the CoO~1 and NH3 groups.
The swelling properties of the hydrogels were studied in buf'f-'er solutions (0.2 M) at p~ = 3.6, 5.0 and 8Ø In Flgures 3(a-c) the swelling capacity, Q, can be observed to increase with a decrease in pH. It follows from Figures 3a, b and c that the swelling capacity is sim:.lar to the hydrogels derived from chitosans with a degree of acetylation of 10 and 28~ which swell with very similar profiles, as shown in our previous work [60]. The swelling characteristics and the water content of the hydrogel are listed in Table 6.
CA 02146192 1997-0~-0 Table 6. Compos;Ltion o~ the swollen hydrogels (spheres) Composition of DAa of Ratiob Hydrogel Chitosan CH/X
(~) (g/g-) Chitosan Xanthan pH ~max~ (w~od) 0.540 40.1 59.9 3.6 90C 90.2 0.540 40.1 59.9 5.0 49Cl 80.4 0.540 40.1 59.9 8.0 25Cl 72.3 28 0.555 24.9 75.1 3.6 80Cl 87.1 28 0.555 24.9 75.1 5.0 56Cl 85.2 28 0.555 24.9 75.1 8.0 26Cl 73.9 34 0.592 24.3 75.7 3.6 68~1 88.4 34 0.592 24.3 75.7 5.0 24Cl 70.3 34 0.5Cl2 24.3 75.7 8.0 17~; 65.2 aDA = degree of acetylation.
bCH/X ratio of chitosan to xanthan C~max maximum hydrogel swelling dW = water content.
Water constitutes, in all cases, the largest weight of the hydrogel. The large swelling capacity of these hydrogels did not lead to disintegration when prepared as microspheres, as in the case for the chitosan-CMC complex [38].
In order to calculate the effective diffusion coefficient of the RBB-xylan in the porous structure of the xanthan-chitosan hydrogels, a series of experiments were performed under conditions similar to those used in the xylanase hydrolysis experiments reported previously by ~ CA 02146192 1997-0~
the inventors [60]. The decrease of the RBB-xylan concentration in the solution was measur~d by the absorption at 595 nm. If the mass transfer inside a hydrogel partic:le is considered to be a pure cliffusional phenomenon, and the particles are assumed to be per~ect spheres with homogeneous physical properties, the nonsteady state process can be described by the equation 6:
~S 1 d ~ 2 ~S ~
~t = D 2 ' d ~ r . ~ ) where S = concentration of substrate (RBB-xylan) M/m3; at position r inside the particle S = S(r) t = time, sec D = diffusion coefficient r = any radius, (comprised between 0 and rp (limit value of radius)) with the following initial and boundary conditions:
1. There is no substrate inside the hydrogel particles at the beginning of the experience.
t = 0 S(r) =- o (0 < r c rp (at any time S(rp) = SE) 2. Due to the spherical symmetry and the homogeneous physical properties, no net transport of substrate occurs from the center of the particle. Thus, at any time:
CA 02146192 1997-0~-0 r = 0 ~S = 0 (t 2 0) ~r 3. The diffusional limitations to mass transfer outside the particle cYan be neglected. Thus, the substrate concentration at the particle-liquid interface is equal to the substrate concentration in the bulk of the liquid phase:
S(rp) = SEP(t) t 2 0 where SEP is the experimentally determined concentration of RBB-xylan in the bulk solution.
Equation (6) combined with a mass balance over the reaction results in the description of the time variation of the substrate concentration in the aqueous phase for a given value of the effective diffusion coefficient. The optimal value of the effective diffusion coef~icient can be obtained from the minimization of the following least squares function-~, [SEP ( tj) - SE ( tj) ] 2 = O
where SE is the RBB-xylan concentration in the bulk solution calculated using Equation (6) and the reaction mass balance for a specified value of the effective diffusion coefficient. By using this m;n;m; zation procedure, an effective diffusion coefficient of 2.02 x 10-12 m2/s was found for RBB-xylan in the xanthan-chitosan hydrogel.
CA 02l46l92 l997-0~-0 The scanning electron microscope (SEM) images of the hydrogels have been obtained for typical gel samples (24 . 25~
chitosan, 75 . 75~ xanthan; data not shown). The images convey the message that the gels are porous and that the formation 5 of fibrillar structures occurred. The channels present in the fibrillar gels have a pore size between 10-7 and 10-6 m (0.11 ~m), whereas the fibrils have a typical dimension of 10-7 m (100 nm). The surface of the microsphere has a homogenous porous structure which allows for the passage of polymeric substrates to the regions where the immobilized enzymes are lodged.
By transmission electron microscope (TEM), images of the hydrogels were obtained (data not shown). The presence of loose aggregates of fibrils was observed, probably 15 resulting from the rupture of the elaborate network, observed via SEM, due to the drying and cutting procedures used. The aggregates were formed by fiber fragments with typical diameters of 50 to 100 nm which is in agreement with the SEM observations. Material structure near the external 20 surface of the sample was also evident. The "open spaces"
(pores) were well developed towards the center of the sample.
For the chitosan-xanthan complex, the percent of immobilization is a function of the concentration of enzyme in the xanthan solution. The yields of 85-98% of the enzyme are present which is far superior to the immobilization yields obtained by other methods [44-47].
The enzymatic activity of the immobilized xylanase (EC
3.2.1.8) increased with respect to the activity of the free enzyme over a wide range of xylanase concentrations in the xanthan solution (0.21 to 1~) as shown in Table 7.
Table 7. Propertiee of the immobilized enzymes in the chitosan-xanthan hydrogele ~0 Enzymes Concentration Meaeured Relative Limit of of Enzymes in Activity' Activityb Thermal the Xanthan (mU/g) (%)Activity Solution (~C) (wt%) Xylanase 0.21 8,889 +69 95c 0.29 11,737 +61 95 0.36 16,000 +77 95 1.00 26,000 +2 98 1.20 28,000 -7 98 Protease 0.29 52,595 0 77d 0.69 67,900 0 77 0.96 72,187 -2 77 1.88 104,294 -8 77 . 2146192 aEnzyme activity refers to the unit weight of dry hydrogel bCalculated with respect to the initial activity of the xylanase (2,500,000 mU/g) and protease (0.4 U/mg) CThermal stability of free xylanase = 45~C
dThermal stability of free protease = 42~C.
Such an increase in activity may be related to a favourable structural effect by the hydrogel on the enzyme through induced electrostatic interactions [48-49]. Such interactions may also explain the observed increase in the thermal stability of the immobilized xylanases which maintained activity up to 98~C.
In the case of the combined xylanase-protease immobilization as well as for xylanase-lipase, a synergistic effect by the xylanase on the protease and lipase activity was observed (Figure 4). Such an effect was also observed in the case of immobilized peroxidase-protease combinations [50]. Due to this synergy, the protease activity was increased by 85-200 with respect to that of the free enzyme. The effect seems to be a function of the incubation time. A decrease in the protease activity with the incubation time of the xylanases could be explained by the saturation of the hydrogel with the products of the hydrolysis of the RBB-xylan [51] which would interfere with the diffusion of the hemoglobin needed for hydrolysis by the protease. The optimum incubation conditions appear to be 10 minutes for the xylanases and 50 minutes for the proteases.
CONCLUSIONS
Hydrogel~ from chito~an and xanthan mixture~ can be readily obtained by ~imple complexation in aqueou~ pha~e within wide pH range~ (3.6 to 8.0), the pH having a great influence on the yield of complexation. The~e gel~ are in~oluble in water and in numerou~ organic ~olvent~. The yield~ of complexed chito~an are a~ high a~ 98%. The CH/X
ratio in the hydrogels and water retention capacity are function~ of the degree of acetylation of chito~an and the CH/X ratio u~ed in the initial ~olution. Hydrogels compri~ing chito~an are ~table in acidic media. Tho~e not containing chito~an (polyba~ic drug~ and xanthan) will ~lowly di~~ociated in acidic media, relea~ing the drug~
from the complex. For tho~e particular hydrogel~, ~u~tained relea~e compo~ition~ are obtained at pH of 6 to about 8. Therefore all the hydrogel~ made in accordance with the pre~ent invention are compatible with all the pH~
encountered in phy~iological condition~. The~e gel~ will therefore find utility for internal a~ well a~ for external u~e (~kin patche~, per o~ compo~ition~, etc.).
The hydrogel~ ~well readily with water content between 65 and 95 wt% to of the total mass which i~ dependent on the cationic component/Xanthan ratio pre~ent in the gel~.
Structural analysis of the gels made of chitosan/xanthan indicate an open fibrillar structure with characteristic pore dimensions between 10-' to 1o-6 m. The fibrils have diameters between 50 and 100 nm.
Due to the immobilization, both the thermal stability and the enzyme activity of the xylanase increased. The protease maintained activity but had lower thermal stability. In the case of the combined immobilization of xylanase and protease, a favourable synergistic effect of the xylanase on the protease activity was observed.
The gels made of chitosan/xanthan can incorporate up to 25~ their weight of enzymes and drugs. The composition of the gels may be modified to optimally accomodate the structure and the charges found on single or organized molecules. The xanthan polyanion has been found paticularly suitable as a constant component of hydrogels.
Therefore, by varying the ratio and the nature of the polycationic components, numerous compositions having the benefit of the present invention are possible.
This invention has been described hereinabove.
Modifications thereto will be readily appreciated by the persons skilled in the art without departing from the spirit and the teachings of the present disclosure. These 2Iq6192 modifications are therefore included in the scope of this invention.
21q6192 REFERENCES
1. Barnett, S. E. and S. J. Varley. 1987. Ann. Roy.
Coll. Surg Eng., 69:153.
2. Burgos, H. 1989. Chitin and Chitosan, S. B. Gudmund, 5T. Anthonsen and P. Sandford, eds., London and New-York: Elsevier Appl. Sci., p. 573.
3. Dumitriu, S. 1992. High Performance Biomaterials, M.
Szycher, ed., Lancaster, PA: Technomic Publishing Co., Inc, p. 669.
104. Dumitriu, S., M. Dumitriu and G. Teaca. 1990.
Clinical Materials, 6:265.
5. Peppas, N. A. and A. G. Mikos. 1986. Hydrogels in Medicine and Pharmacy, Vol. 1, Fundamentals, N. A.
Peppas, ed., Boca Raton, FL: CRC Press, Inc, pp 2-24.
156. Yoshioka, T., R. Hirano, T. Shioya and M. Kaka 1990.
Biotechnol. Bioeng, 35:66.
POLYIONIC INSOLUBLE HYDROGELS COMPRISING XANTHAN
FIELD OF THE lNV~. 1 lON
This invention relates to hydrogels made of polyionic complexed molecules, particularly to hydrogels for use in slow release formulations of blologically active molecules.
R~R~OUND OF THB lNVL~ ON
Hydrogels can be classified into two broad categories: reversible and irreversible. The former are characterized by significant changes in the rheological properties as a function of temperature, ionic concentration, and dilution. Irreversible hydrogels are soluble in water, as well as in other solvents, over a wide range of temperatures and dilutions. Due to their solubility profiles, irreversible hydrogels have multiple applications in food, cosmetics, medicine and biotechnology [1-5]. The preparation of hydrogels can be achieved by a variety of methods: reticulation of linear polymers; grafting of synthetic polymers onto naturally occurring macromolecules; chelation of polycations; and complexation between polyanions and polycations [6-8].
- ' 21461~2 Chitosan, the deacetylated form of chitin (N-acetyl glucosamide), has polycationic properties and forms, with polyanions, water insoluble hydrogels [9-14]. These have been successfully used as a support material for the immobilization of enzymes and cells [15-20] and for controlled drug release [20-24]. The immobilization of enzymes using organic and inorganic matrices has been widely studied [25-30] and a variety of immobilization methods such as chemical reaction, microencapsulation, and adsorption on various surfaces have been used [31-34]. Our attention has focused on enzyme immobilization using hydrogels because their hydrophilicity allows, in principle, for the creation of microsystems favourable for enzymatic activity. Complexes of cationic polymers have been prepared with different polyanions like synthetic polyanions (polyacrylic, polymethacrylic acids and polyvinyl alcohol sulfate [52-54]; natural polyanions (alginate, heparin, carrageenan, pectin, glycosaminoglycanes [55-60]; cellulosic derivatives (carboxymethylcellulose and oxydized cellulose [61-62]).
Complexes of natural polyions such as chitosan, carboxymethylcellulose and alginic acid are already known [35,37,38], and enzymes and other bioactive compounds have been immobilized or lodged therein [39-41]. All the hydrogels known in the art have however a capacity of CA 02146192 1997-0~-0~
encapsulation oi biological products (medication, enzymes and cells) which retention yield is very low, v~rying from 1 to 8%. In all these cases, the enzymes conserve only 50 ~ of their initial activity. Therefore, there is clearly a need ~or polyionic hydrogels showing a more per~orming retention yield as well as an improved activity for the retained enzymes~.
SUMMARY OF THE lNv~llON
It is an object of the presen~ invention to provide hydrogels having high retention yields of biological products. Not only do the hydrogels of this invention have a very good retention yield, they also preserve and/or enhance the activity of complex molecules like proteins and enzymes immobilized therein. These hydrogels comprise a polycationic molecule like chitosan or polybasic drugs as a natural polycation complexed with xanthan as a po]yanion.
In a preferred embodiement, the polycationLc molecule is chitosan. Hydrogel composition depends on the acetylation deg:ree of the chitosan which will determine the charges of this compound and its ability to complex to xanthan. The swelling capacity of the hydrog~ls depends on the molecular weight of the chitosan component, its CA 02146192 1997-0~-0~
acetylation degree and also on the surface area of the prepared products, being microspheres, spheres and films/sponges.
In a prer~e3-red embodiement 03~ the present invention, the biological products encapsulated and immobilized in chitosan/xanthan hydrogels are enzymes. For all enzymes tested, as sing]e or combined enzymes, the retention yield varies ~rom 80 to 98~. The enzymes are included in proportions that are up to 25~ of the hydrogel mass.
These enzymes a-îe slowly -Leleased by diLLusi~ln from che hydrogels. When compared to the activity of the free enzymes, the activity of encapsulated enzymes may be improved by 2 or 3 fold.
In another embodiement of the invention, a large panel 03' neutral drugs have been encapsulated in chitosan/xanthan hydrogels. These neutral drugs have been shown to be released from the gels following zero order kinetics.
In another embodiement of the invention, polybasic drugs have been complexed with xanthan with or without chitosan. This system releases the drug at neutral and acidic pHs also following a zero order kinetics.
The advanrages of the hydrogels of the present invention are conferred by the preservati~n of the biological activities of the immobilized molecules. Also, 21~C192 the hydrogels containing chitosan are stable in acidic pHs, a characteristic very useful for per os administration of medications. The hydrogels will desintegrate only in basic solutions which pH is equivalent to the pH of a 10~ NaOH solution. The hygrogels are therefore stable in all encountered physiological pHs. When polybasic drugs are directly complexed with xanthan, the former are slowly dissociated from the latter in acidic conditions and the speed of dissociation decreases as the pH increases. A sustained release is achieved at pH of 6 to about 8, which makes the compositions useful for external use (applied to the skin pH 6.5) as well as for internal use.
DESCRIPTION OF THB lNVlSL~ 1~ lON
Hydrogels made of polycationic and polyanionic compounds have been the subject of many studies. A study conducted by Kim and Rha [37] has shown that hydrogels might be good substrates for immobilized cells. The results obtained with regard to improved cell adhesion and growth cannot however be applied to predict the improvement of immobilization and activity of molecules like enzymes. The conformation of enzymes is rarely predictable and the enzymes are most often very capricious towards environmental conditions that will determine their CA 02146192 1997-0~-0~
conformation and their degree of activity. Therefore, even though the encapsulation o~ cells has been made with success, encapsulation of enzymes has not shown a great improvement with regard to the retention of enzymes in hydrogels and most importantly, the preservation of the biological activity of such encapsulated enzymes.
The use of natural polyanionic substances in the formation of complexes with polycations is already known.
Indeed, alginates, heparin, carrageenan, pectin, glycosaminoglycans have already been tried. However, the retention capacity of complex molecules like enzymes in these hydrogels is far from excellent (between 1 and 8~).
Moreover, the enzymes immobilized in these hydr~gels loose about 50~ of their activity. Xanthan ii3 a known polyanion. Although this polysaccharide produced by Xanthomonas campestris might be on first sight another natural polyanion among others, its complexation with a polycation like chitosane has revealed, in accordance with the present invention suprisingly good properties with regard to the retention yield of enzymes and the preservation o:r enhancement of the activity of such immobilized enzymes.
In the present invention, other polycations might be used in lieu of chitosane. For example, a complex made of xanthan and polybasic drugs have provided good insoluble hydrogels having high retention capacities and showing stability in acidic media.
A full description of this invention is made hereinbelow by way of examples and figures which purpose is to illustrate the invention rather than to limit its scope.
BRIEF DESCRIPTION OF THE FIGURES:
Figure 1 shows the complexation yield of chitosan as a function of the chitosan/xanthan ratio for three samples of chitosan having different acetylation degrees (10, 28 and 34~). pH of the solution: 6.3.
Figure 2 shows the complexation yield of chitosan as a finction of the quantity of chitosan in a 123 mL
solution with 0.4 g xanthan. pH of the solution: 6.3.
Figures 3a, b and c show the swelling capacity (Q) as a function of time at different pHs: 3.6, 5.0 and 8Ø
The chitosan has an acetylation degree of 10~.
Figure 4 shows the relative xylanase activity when immobilized in hydrogels alone or co-immobilized in the same with protease (PR) or lipase (LI) as a function of the concentration of xylanase in the solution of xanthan introduced into the solution of chitosan.
21~6192 MATT~T~T.'.~: AND hh~ VS
Xanthan (X) (Aldrich, batch no. 08403HY) was purified by dissolution in water (1 wt~ of xanthan) and precipitation with isopropyl alcohol. Four dissolution-precipitation cycles were used to lower the N
content from 0.7 wt~ (initial xanthan) to 0.15 wt~ in the purified xanthan. The latter was dissolved again in water (1 wt~), precipitated with ethyl alcohol (50/50 v/v), filtered and rinsed with ethyl alcohol/water mixtures (varying from 2/1 to 1/2 by volume). The resultant xanthan was again dissolved in water (1.5 wt%) and lyophilized. The N content was 0.09 wt%. Solutions of this xanthan were prepared by adding 3.5, 5.45 and 6.5 g to 1000 mL of water for preparing microspheres, spheres and films, respectively.
Chitosan (CH) were dissolved in 300 mL of 0.1 N HCl.
- The solution neutralized with 0.1 N NaOH, and distilled water was added for a total volume of 1000 mL at pH = 6.3.
Two chitosan samples with degrees of acetylation (DA) of 28~ and 10~ were derived from the Sigma chitosan (DA =
34~; batch no. C-0792) using alkaline hydrolysis (30 NaOH) at room temperature for 1 h and 2.5 h, respectively.
'_ 2146192 g Example 1 The hydrogel was prepared by mixing 61.5 mL of the chitosan solution with 61.5 mL of the xanthan solution.
Agitation was conducted for 10 min at room temperature and the hydrogel formed was separated out by centrifugation at 3000 rpm. The hydrogel was washed repeatedly with water to remove the free chitosan and xanthan which were monitored for in the wash water by HPLC (xanthan and chitosan) and by titration of the amine groups on chitosan.
Example 2 The chitosan (CH/X) hydrogels were also prepared as spheres in the following way: 30 mL of the chitosan solution were added dropwise, with a syringe, into 20 mL
of the xanthan solution previously degassed. Spheres formed under mild agitation at room temperature. The spheres were collected and washed with an acetate buffer solution (0.2 M, pH = 3.6) to eliminate the excess free chitosan. The spheres were then rinsed with water. The spheres were kept in an acetate buffer, 0.25 M, at pH =
3.6.
Example 3 Solutions of chitosan (having different degrees of acetylation (10, 28 and 34~) were prepared as follows: 6.5 ~ 2146192 g chitosan were dissolved in 1~ acetic acid and precipitated with 10~ NaOH. The precipitated chitosane was successively washed with water (4-5 L), alcohol/water (50/50 v/v) alcohol (95~). The purified chitosane was then dried by lyophilization. Different solutions of chitosan were made as follows:
- For microspheres, 3.5 g chitosane were dissolved in 100 mL HCl lN, neutralized with NaOH lN till a pH= 3.8 is obtained, and then the volume of the solution was made one liter with water. The electrolyte concentration was 0.09 M NaCl;
For spheres (1-2 mm), 5.45 g chitosan were dissolved in 300 mL HCl lN, neutralizes with NaOH lN till a pH= 5.5 was obtained, and the volume of the solution completed to one liter with water. The electrolyte concentration 0.18 M NaCl;
For films, 6.5 g chitosan were dissolved in 300 mL
HCl lN, neutralized with NaOH lN till a pH=6.5 was obtained. After volume completion to one liter with water, the electrolyte concentration was 1.8 M NaCl.
Solutions of chitosan and xylan are degazed.
For preparing the microspheres, to 20 mL of a 0.35~
xanthan solution placed in a reactor with an agitating system is added 20 mL of a 0.35~ chitosan solution with the aid of a seringe of a diameter of .1 mm. The diameter '~- ' 2l~6l92 of the microspheres depend on the speed of agitation, the seringe diameter and the speed of introduction of chitosan in the xanthan solution. We have tested a speed of agitation of 500 rev./min. and a speed of introduction of chitosan of 0.5-2 mL/min. After the addition of chitosane is completed, the mixture is kept under agitation for 30 minutes. The reaction mixture is then diluted with 200 mL
acetate buffer 0.1 M pH=5.6. The microspheres are are decanted and washed with 500 mL of the same buffer until no free xanthan or chitosan is left (verified by isopropyl alcohol precipitation for xanthan and by NaOH 10 N
precipitation for chitosan). The microspheres are kept in in the same buffer for further use.
For preparing the spheres, a 20 mL chitosan solution (0.545%) is introduced in a reactor, and a 20 mL xanthan solution of varying concentration is added at a speed of introduction of 0.5 mL/min with the aid of a 0.2-0.5 mm diameter seringe under low speed of agitation to avoid aggregation of the spheres. The preparation is further processed like for the microspheres. The spheres have a diameter varying from 1.5 to 2 mm diameter.
For preparing films, 12 mL of a xanthan solution (0.65%) was poured into a 100 mm Petri plate. On a perfectly plane surface, the solution was allowed to rest for at one hour to obtain a layer of homogenous thickness.
21g6192 20 mL of a chitosan solution was added with a seringe, taking care for not disturbing the xanthan layer. These two phases are allowed to stay for two hours. The formed film is taken from the plate walls. The reaction further proceeds at room temperature for at least four days. The solution formed at the top of the film is withdrawn with a seringe, and the film is washed in the following successive solutions:
-10 mL acetate buffer 0.1 M, pH 5.3 (3 X 30 minutes);
-10 mL CaCl2 1~ (2 X 30 minutes);
-10 mL NaCl 2~ (4 X 30 minutes); and -25 mL water (5 X 30 minutes).
Sponges can be also made following substantially the same procedure as for preparing films, but changing the drying procedures for enhancing the size of the pores formed in the films.
The reaction yields were determined using the following relationship:
yield = (weight of dry gel) X 100 (weight of chitosan) + (weight of xanthan) 21~6I92 The degree of swelling, ~, of the hydrogels was determined by weighing the dry hydrogels before and after immersion in the acetate buffer at 2 min intervals, and was defined as:
a = (weight of hydrated gel) - (weight of dry gel) X 100 (weight of dry gel) By plotting ~ versus time of immersion the saturation value was determined when a reaches a plateau, which corresponded to ~m~. From this plot, the swelling capacity, Q, was determined:
Q = [weight of gel at maximum swelling]
[weight of dry gel]
The water content, W, of the hydrogel at equilibrium was determined by:
(weight of gel at maximum swelling) -W = . (weight of dry gel) X 100 (welght of gel at maximum swelling) The degree of acetylation, DA, of chitosan was determined from elemental N analysis data using the following relationship:
DA =[(8.695 ~ %~ X 100 where 8.695 is the %N of a completely deacetylated chitosan, and 1.799 is the difference between 8.695 and 6.896. This latter value is the N~ in completely acetylated chitin.
The FTIR spectra were carried out using a Nicolet (model 5DXB) spectrometer operated in the 400-4600 cm~
region, and 400 scans were collected at a resolution of 4 cm~l. The samples were prepared by mixing KBr with either chitosan, xanthan or the polygel. Typically, 3.5 mg of organic material were mixed with 350 mg of KBr. The mixture was well blended and finely ground for 1 min after which a pellet was prepared at a pressure of 1.0 MPa. The pellet was dried under vacuum, at room temperature, for a period of 24 h in the presence of P2O5.
The hydrogel samples to be used for the transmission and scanning electron microscopic observations (TEM, SEM) were stabilized with glutaraldehyde (1 wt%) in a 0.1 M
phosphate buffer at pH = 7.2 for 15 to 60 min at 4~C. Then these samples were washed repeatedly with a 0.1 M
phosphate buffer solution. The samples were then post-fixed in 1% osmium tetroxide (OSO4) in a 0.1 M
21~6192 phosphate buffer at pH = 7.2 for 24 h at 4~C. After repeated washings with the buffer solution, the samples were dehydrated sequentially with ethanol solutions with increasing ethanol concentration (30, 50, 70, 90, 95, 100 vol~).
For SEM, the ethanol impregnated gel samples were totally dried by the critical point drying method (CPD) using CO2. The dried samples were then fixed on aluminium sample holders using a silver based adhesive. The samples were made conductive by sputter coating (Anatech Ltd., model Hummer VI) with a 15 nm layer of Au/Pd. A JEOL
JSM-840A scanning electron microscope operated under an accelerated voltage of 15 or 20 kV was used for the observations.
For TEM, the samples were dehydrated with 100~
ethanol, placed into liquid propylene oxide for a few minutes and then into a 1:1 mixture of propylene oxide and epoxy resin (EPON) overnight. After that, the samples were transferred into pure epoxy resin and placed in an oven at 60~C for 48 h to polymerize. After polymerization, ultra-thin sections, 600 A in thickness, were made and stained with uranyl acetate and lead citrate. The thin sections were e~m;ned under a Philips EM 300 transmission electron microscope at an accelerating voltage of 60 kV.
_ ' 214619~
The immobilization of the enzymes was carried out as follows: to an a~ueous solution of xanthan (0.65 wt~), the enzymes [endo-1,4-~-xylanase from Trichoderma viride, 2.5 U/mg (Fluka); protease type XIX fungal from Aspergillus 5 sojae, 0.4 U/mg (Sigma); or enzyme mixtures at various ratios] were added at concentrations varying between 0.5 and 1.8 wt~. The solution was agitated for 15 min at 15~C
and introduced dropwise, with a syringe, into the chitosan solution. The latter was adjusted to pH = 6.3 for the protease preparations and to pH = 4.3 for the xylanase preparations alone. The microspheres formed were agitated for 15 minutes at room temperature (20-22~C) and washed with an acetate buffer (0.5 M, pH = 5.3). They were then kept at 5~C in an acetate buffer (0.05 M, pH = 5.3).
The enzymatic activity of the immobilized xylanase and protease was determined using the following established methods [42-43].
Protease As~ay A 2~ hemoglobin solution was prepared by dissolving (with gentle stirring) 5 g of hemoglobin substrate powder (SIGMA) in a solution of 80 g of urea in 80 mL of water.
After incubation at 37~C for 60 min, 50 mL of 0.25 M
buffer were added. The pH was adjusted to 7.2 and then the solution was diluted to 250 mL with water. When casein or other protein was used, the substrate solution could be prepared without urea. All the solutions were equilibrated at 25~C before use. The assay was started by adding 5 mL
of temperature-equilibrated substrate solution to 0.02 g of immobilized protease and mixed thoroughly but gently to prevent frothing. The mixture was incubated at the desired temperature for a fixed period of time not exceeding 10 min. Multiple assays were performed by adding substrate to successive tubes in 30 sec intervals. The reactions were terminated in the same sequence. At the end of the incubation period, the reaction was terminated by adding 10 mL of 5~ trichloroacetic acid to the assay mixture. A
blank was prepared by combining the trichloroacetic acid with the immobilized enzyme and then substrate was added.
The assay mixture and blank were allowed to stand for 30 min. The precipitate material was removed by centrifugation. The absorbance of the supernatant was measured at 280 nm, with reference to the blank. One unit of enzyme activity is defined as the amount of enzyme required to cause a unit increase in absorbance at 280 nm across a 1 cm path length, under the conditions of the assay. The enzymatic activity was expressed in activity units per unit weight of the dry microsphere.
21~6192 Xylanase Aseay A Remazol Brilliant Blue R-Xylan (RBB-xylan) solution in 0.05 M acetate buffer, pH 5.4, 5.75 mg/mL was used.
Immobilized enzyme (0.02 g) was mixed with 0.5 mL of preheated (30~C) RBB-xylan (5.75 mg/mL) solution and incubated at 30~C. The reaction was terminated by the addition of 1 mL of ethanol to precipitate the unhydrolyzed RBB-xylan and the high molecular weight fragments. After standing for 30 min at room temperature (thermal equilibration of samples), the precipitated substrate was recovered by centrifugation at 2000 g for 1.5 min. The absorbance of supernatant was measured at 595 nm against the respective substrate blank. The enzymatic activity was expressed in activity units per unit weight of the dry microsphere. The effective diffusion coefficient of RBB-xylan in the hydrogel was calculated from the changes in the solution concentration determined by absorption at 595 nm.
Other assays using cells, drugs and enzymes:
The behavior of other immobilized and co-immobilized enzymes (lipase and hemicellulase with or without xylanase) has also been verified. Furthermore, chitosan/xanthan hydrogels incorporating neutral drugs have been made. TYpical neutral drugs include CA 02146192 1997-0~-0~
.
cephalosporin, t:etracyclin, oxytetracyclin, sulfathiazole, metronidazole, chloramphenicol, daunorubicin, ampicilin, penicilin, eryt;hromycin, quinidine, alacacinomycin and mithramycin. The same hydrogels may also be used as a support for eucaryotic and procaryotic cells. Gels can also be made by substituting a part or the totality of the chitosan by other polycations. Examples of polycations are polybasic drugs like gentamycin, bleomycin, anthelmycin, enzomycin A, vancomycin, t:richomycin, adenomycin, orthomycin, neomycin, kanamycin and sisomycin.
RESULTS AND DIS~CUSSION
The complexation reaction between the polyions leads to structural changes in both xanthan and chitosan polymers. A water insoluble hydrogel was formed by blocking the hydrophillic functions (R-COOH in case of polyanions and R'-NH2 for the polycations) and by the interaction between the macromolecular chains. The latter effect createcl an "ionic" reticular net:work that immobilized the polymers. The hydrogel formed incorporated a significant amount of water and was ,-apable of stabilizing biological products in the matrix.
We studied the complexation reaction between xanthan and chitosan by determining the yields and the structure of the complexes formed as well as th,- swelling 21~6192 capacities. Three chitosan samples with degrees of acetylation (DA) of 10, 28 and 34~ were used. Figures 1 and 2 show the efficiency (yield) of the complexation reaction as a function of the xanthan/chitosan ratio and the mass concentration of chitosan, respectively. The complexation efficiency was as high as 90% of the available chitosan. The less deacetylated chitosan (DA =
34%) formed a stable hydrogel with the highest chitosan/xanthan ratio. In fact, the lower the DA the greater amounts of xanthan were needed to form a stable hydrogel.
For the same degree of acetylation (DA= 10~), the yield of formation of spheres, microspheres and films depends on the chitosan/xanthan ratio, as shown in Table 1.
Table 1. Variation in the complexation yield as a function of the CH/X ratio for various forms of hyd,G~el~
Yield of complexation (~) Ratio CH/X
(g/g) Microspheres Spheres Films 0.2 89 90 98 0.5 98 87 93 0.7 85 83 90 0.9 76 81 73 1.2 58 69 53 The chitosan content of the hydrogel (spheres) was determined from the N content which depended upon the degree of chitosan acetylation and, to a lesser extent, on the CHjX ratio used in the complexation reaction, as shown in Table 2.
Table 2. Composition of the hydrogels a~ a function of the degree of acetylation Ratio N Content Composition CH/X' of Sample (g/g) Hydrogel Chitosan Xanthan (%) (%) (%) 1 0.4923.30 38.861.2 2 0.5073.38 39.760.3 3 0.5403.41 40.159.9 4 0.5703.52 41.458.6 0.5552.04 24.975.1 6 0.5802.28 27.872.2 7 0.6422.31 28.271.8 8 0.7072.40 29.370.7 9 0.5921.96 24.375.7 0.6282.10 26.074.0 11 0.7202.25 27.872.2 12 0.8072.38 29.570.5 Sample % N in Chito~an DA (%) b 1-4 8.51 10 5-8 8.19 28 9-12 8.08 34 aCH/X = chitosan to xanthan.
bDA = degree of acetylation.
The results indicate that a higher DA lowered the chitosan content of the complex due to a decrease in the free amine available for complexation. The chitosan content in the hydrogel increased with the CH/X ratio in the reaction.
The method of preparation of the hydrogels (microspheres, spheres and films) was determinant in their composition, as shown in Table 3.
Table 3.
Composition (~) Hydrogel Types Chitosan Xanthan 10Microspheres 46.1 53.9 Spheres 39.7 60.3 Films 26.8 73.2 Initial CH/X = 0.5 g/g; DA chitosan = 10~; Mn chitosan =
691,390. The pH value is specific to each type of preparation (See Materials and Methods) We studied the influence of the pH of the chitosan solution on the yield of complexation with xanthan. The results are shown in Table 4.
CA 02146192 1997-0~-0~
.
Table 4. Influence of the pH of the chil;osa.n solution (0.65 wt%) on the complexation ~ith xanthan pH Xanthan Comp~e~a-tion (%) 1.~; 21 2.~; 36 3.5 56 4.5 60 5.5 78 6.3 9~
Chitosan to xanthan ratio (CH/X) = 0.65 g/g.
M chitosan = 691,390 determined by measuring the intrinsic viscosity.
[~] = 1.81 x 10-3 M093; the value 0.93 being determined in 0.1 M acetic ac:id/0.2 M NaCl solution at 25~C [36].
Poor complexation at low pHs was observed due to strong protonation of t:he amine groups which impeded t:he reaction with the carboxylic groups present in the xanthan. Similar results have been reported for the complexation of chitosan with CMC and alginic acid [37-38].
The molecular weight of chitosan ha.d a strong influence on the properties of the hydrogel, particularly the water rete:ntion capacity and the solubility under basic conditions. The effect of molecular weight on water retention was st,udied using four samples of ch.itosan with similar degrees of acetylation but molecular weights varying from 69:L,930 to 122,350. The results a:re shown in Table 5.
CA 02l46l92 l997-0~-0 Table 5. Influexlce of the molecular weight of ~hitosan on the absorption ~f water by the chi.tosan-xanthan hydrogel Chitosana DAb of Co~Lplexation ~ c M~ Chitosan (%) Yield (~) (%) 5691,930 28.0 98.9 560 452 r 875 27.9 97.2 805 191,325 28.2 84.5 992 122 r 350 28.8 81.3 1050 a Determined by measuring the intrinsic viscosity [~] =
1.81 x 10-3 M0-93 in 0.1 M acetic acid/O. 2 M NaCl ,301ution at 25~C [36] .
bDA = degree of acetylation.
C~max = maximum hydrogel swelling.
pH = 5.0: buffer acetate 0. 2 M.
15 The decomposition of the chitosan-xanthan hydrogel in basic media depended on the pH and the ionic concentration of the buffer solution. In the pH range between 7.0 and 9.2~ the hydrogel is stable and independent of- the ionic concentration. At pH > 9. 2 ~ decomposition of the complex 20 begins at 2 M concentration. In a 10 wt~ NaOH solution the complex broke down completely.
The FTIR spectra of the hydrogels have the characteristic absorption bands of chitosan and xanthan (data not shown). The chitosan spectrum has the following 25 characteristic absorption bands: the amide I band (C=O
stretching vibration at 1653 cm~l) and amide I:[ band (N-H
bending and C-N stretching). The spectrum shows that the material has a low degree of acetylation at 1599 cm~1 and CA 02146192 1997-0~-0~
shoulder at 1563 cm~1. The characteristic bands :or xanthan are due to C=O stretching of. the ester groups a.t 1730 cm~
and of the H-bo:nded or ionized carboxylic groups at 1650 cm~1 and lower f'requencies. Complexation did not affect the behaviour of' the ester group which showed clS expected a less intense absorption around 1730 cm~1. Al]. the other C=O absorptions from carboxylic groups mentioned above collapse after complexation to form a single large band centered at 1620 cm~1. The amide II is seen as a shoulder.
We noted that the 1620 cm~1 band in the chitosan-xanthan gel is stronger than that of xanthan due to the conjugation between the CoO~1 and NH3 groups.
The swelling properties of the hydrogels were studied in buf'f-'er solutions (0.2 M) at p~ = 3.6, 5.0 and 8Ø In Flgures 3(a-c) the swelling capacity, Q, can be observed to increase with a decrease in pH. It follows from Figures 3a, b and c that the swelling capacity is sim:.lar to the hydrogels derived from chitosans with a degree of acetylation of 10 and 28~ which swell with very similar profiles, as shown in our previous work [60]. The swelling characteristics and the water content of the hydrogel are listed in Table 6.
CA 02146192 1997-0~-0 Table 6. Compos;Ltion o~ the swollen hydrogels (spheres) Composition of DAa of Ratiob Hydrogel Chitosan CH/X
(~) (g/g-) Chitosan Xanthan pH ~max~ (w~od) 0.540 40.1 59.9 3.6 90C 90.2 0.540 40.1 59.9 5.0 49Cl 80.4 0.540 40.1 59.9 8.0 25Cl 72.3 28 0.555 24.9 75.1 3.6 80Cl 87.1 28 0.555 24.9 75.1 5.0 56Cl 85.2 28 0.555 24.9 75.1 8.0 26Cl 73.9 34 0.592 24.3 75.7 3.6 68~1 88.4 34 0.592 24.3 75.7 5.0 24Cl 70.3 34 0.5Cl2 24.3 75.7 8.0 17~; 65.2 aDA = degree of acetylation.
bCH/X ratio of chitosan to xanthan C~max maximum hydrogel swelling dW = water content.
Water constitutes, in all cases, the largest weight of the hydrogel. The large swelling capacity of these hydrogels did not lead to disintegration when prepared as microspheres, as in the case for the chitosan-CMC complex [38].
In order to calculate the effective diffusion coefficient of the RBB-xylan in the porous structure of the xanthan-chitosan hydrogels, a series of experiments were performed under conditions similar to those used in the xylanase hydrolysis experiments reported previously by ~ CA 02146192 1997-0~
the inventors [60]. The decrease of the RBB-xylan concentration in the solution was measur~d by the absorption at 595 nm. If the mass transfer inside a hydrogel partic:le is considered to be a pure cliffusional phenomenon, and the particles are assumed to be per~ect spheres with homogeneous physical properties, the nonsteady state process can be described by the equation 6:
~S 1 d ~ 2 ~S ~
~t = D 2 ' d ~ r . ~ ) where S = concentration of substrate (RBB-xylan) M/m3; at position r inside the particle S = S(r) t = time, sec D = diffusion coefficient r = any radius, (comprised between 0 and rp (limit value of radius)) with the following initial and boundary conditions:
1. There is no substrate inside the hydrogel particles at the beginning of the experience.
t = 0 S(r) =- o (0 < r c rp (at any time S(rp) = SE) 2. Due to the spherical symmetry and the homogeneous physical properties, no net transport of substrate occurs from the center of the particle. Thus, at any time:
CA 02146192 1997-0~-0 r = 0 ~S = 0 (t 2 0) ~r 3. The diffusional limitations to mass transfer outside the particle cYan be neglected. Thus, the substrate concentration at the particle-liquid interface is equal to the substrate concentration in the bulk of the liquid phase:
S(rp) = SEP(t) t 2 0 where SEP is the experimentally determined concentration of RBB-xylan in the bulk solution.
Equation (6) combined with a mass balance over the reaction results in the description of the time variation of the substrate concentration in the aqueous phase for a given value of the effective diffusion coefficient. The optimal value of the effective diffusion coef~icient can be obtained from the minimization of the following least squares function-~, [SEP ( tj) - SE ( tj) ] 2 = O
where SE is the RBB-xylan concentration in the bulk solution calculated using Equation (6) and the reaction mass balance for a specified value of the effective diffusion coefficient. By using this m;n;m; zation procedure, an effective diffusion coefficient of 2.02 x 10-12 m2/s was found for RBB-xylan in the xanthan-chitosan hydrogel.
CA 02l46l92 l997-0~-0 The scanning electron microscope (SEM) images of the hydrogels have been obtained for typical gel samples (24 . 25~
chitosan, 75 . 75~ xanthan; data not shown). The images convey the message that the gels are porous and that the formation 5 of fibrillar structures occurred. The channels present in the fibrillar gels have a pore size between 10-7 and 10-6 m (0.11 ~m), whereas the fibrils have a typical dimension of 10-7 m (100 nm). The surface of the microsphere has a homogenous porous structure which allows for the passage of polymeric substrates to the regions where the immobilized enzymes are lodged.
By transmission electron microscope (TEM), images of the hydrogels were obtained (data not shown). The presence of loose aggregates of fibrils was observed, probably 15 resulting from the rupture of the elaborate network, observed via SEM, due to the drying and cutting procedures used. The aggregates were formed by fiber fragments with typical diameters of 50 to 100 nm which is in agreement with the SEM observations. Material structure near the external 20 surface of the sample was also evident. The "open spaces"
(pores) were well developed towards the center of the sample.
For the chitosan-xanthan complex, the percent of immobilization is a function of the concentration of enzyme in the xanthan solution. The yields of 85-98% of the enzyme are present which is far superior to the immobilization yields obtained by other methods [44-47].
The enzymatic activity of the immobilized xylanase (EC
3.2.1.8) increased with respect to the activity of the free enzyme over a wide range of xylanase concentrations in the xanthan solution (0.21 to 1~) as shown in Table 7.
Table 7. Propertiee of the immobilized enzymes in the chitosan-xanthan hydrogele ~0 Enzymes Concentration Meaeured Relative Limit of of Enzymes in Activity' Activityb Thermal the Xanthan (mU/g) (%)Activity Solution (~C) (wt%) Xylanase 0.21 8,889 +69 95c 0.29 11,737 +61 95 0.36 16,000 +77 95 1.00 26,000 +2 98 1.20 28,000 -7 98 Protease 0.29 52,595 0 77d 0.69 67,900 0 77 0.96 72,187 -2 77 1.88 104,294 -8 77 . 2146192 aEnzyme activity refers to the unit weight of dry hydrogel bCalculated with respect to the initial activity of the xylanase (2,500,000 mU/g) and protease (0.4 U/mg) CThermal stability of free xylanase = 45~C
dThermal stability of free protease = 42~C.
Such an increase in activity may be related to a favourable structural effect by the hydrogel on the enzyme through induced electrostatic interactions [48-49]. Such interactions may also explain the observed increase in the thermal stability of the immobilized xylanases which maintained activity up to 98~C.
In the case of the combined xylanase-protease immobilization as well as for xylanase-lipase, a synergistic effect by the xylanase on the protease and lipase activity was observed (Figure 4). Such an effect was also observed in the case of immobilized peroxidase-protease combinations [50]. Due to this synergy, the protease activity was increased by 85-200 with respect to that of the free enzyme. The effect seems to be a function of the incubation time. A decrease in the protease activity with the incubation time of the xylanases could be explained by the saturation of the hydrogel with the products of the hydrolysis of the RBB-xylan [51] which would interfere with the diffusion of the hemoglobin needed for hydrolysis by the protease. The optimum incubation conditions appear to be 10 minutes for the xylanases and 50 minutes for the proteases.
CONCLUSIONS
Hydrogel~ from chito~an and xanthan mixture~ can be readily obtained by ~imple complexation in aqueou~ pha~e within wide pH range~ (3.6 to 8.0), the pH having a great influence on the yield of complexation. The~e gel~ are in~oluble in water and in numerou~ organic ~olvent~. The yield~ of complexed chito~an are a~ high a~ 98%. The CH/X
ratio in the hydrogels and water retention capacity are function~ of the degree of acetylation of chito~an and the CH/X ratio u~ed in the initial ~olution. Hydrogels compri~ing chito~an are ~table in acidic media. Tho~e not containing chito~an (polyba~ic drug~ and xanthan) will ~lowly di~~ociated in acidic media, relea~ing the drug~
from the complex. For tho~e particular hydrogel~, ~u~tained relea~e compo~ition~ are obtained at pH of 6 to about 8. Therefore all the hydrogel~ made in accordance with the pre~ent invention are compatible with all the pH~
encountered in phy~iological condition~. The~e gel~ will therefore find utility for internal a~ well a~ for external u~e (~kin patche~, per o~ compo~ition~, etc.).
The hydrogel~ ~well readily with water content between 65 and 95 wt% to of the total mass which i~ dependent on the cationic component/Xanthan ratio pre~ent in the gel~.
Structural analysis of the gels made of chitosan/xanthan indicate an open fibrillar structure with characteristic pore dimensions between 10-' to 1o-6 m. The fibrils have diameters between 50 and 100 nm.
Due to the immobilization, both the thermal stability and the enzyme activity of the xylanase increased. The protease maintained activity but had lower thermal stability. In the case of the combined immobilization of xylanase and protease, a favourable synergistic effect of the xylanase on the protease activity was observed.
The gels made of chitosan/xanthan can incorporate up to 25~ their weight of enzymes and drugs. The composition of the gels may be modified to optimally accomodate the structure and the charges found on single or organized molecules. The xanthan polyanion has been found paticularly suitable as a constant component of hydrogels.
Therefore, by varying the ratio and the nature of the polycationic components, numerous compositions having the benefit of the present invention are possible.
This invention has been described hereinabove.
Modifications thereto will be readily appreciated by the persons skilled in the art without departing from the spirit and the teachings of the present disclosure. These 2Iq6192 modifications are therefore included in the scope of this invention.
21q6192 REFERENCES
1. Barnett, S. E. and S. J. Varley. 1987. Ann. Roy.
Coll. Surg Eng., 69:153.
2. Burgos, H. 1989. Chitin and Chitosan, S. B. Gudmund, 5T. Anthonsen and P. Sandford, eds., London and New-York: Elsevier Appl. Sci., p. 573.
3. Dumitriu, S. 1992. High Performance Biomaterials, M.
Szycher, ed., Lancaster, PA: Technomic Publishing Co., Inc, p. 669.
104. Dumitriu, S., M. Dumitriu and G. Teaca. 1990.
Clinical Materials, 6:265.
5. Peppas, N. A. and A. G. Mikos. 1986. Hydrogels in Medicine and Pharmacy, Vol. 1, Fundamentals, N. A.
Peppas, ed., Boca Raton, FL: CRC Press, Inc, pp 2-24.
156. Yoshioka, T., R. Hirano, T. Shioya and M. Kaka 1990.
Biotechnol. Bioeng, 35:66.
7. Crescenzi, V., M. Dentini and R. Rizzo. 1981. ACS
Symposium Series, 150:331.
Symposium Series, 150:331.
8. Shioya, T. and C. K. Tha. 1989. Chitin and Chitosan, 20S. B. Gudmund, T. Anthonsen, and P. Sandford, eds., London and New York: Elsevier Appl. Sci., p. 627.
9. Lemainque, A., J. Braun and F. Goffic 1988. Eur. J.
Biochem., 174:171.
Biochem., 174:171.
10. Paulmann, H., H. Doernenburg and D. Knorr. 1990.
25International Conference on Biotechnology and Food, 21~6192 Stuttgart, Germany, February 20-24, 1989, Food Biotechnol. N.Y. (1) p. 484.
25International Conference on Biotechnology and Food, 21~6192 Stuttgart, Germany, February 20-24, 1989, Food Biotechnol. N.Y. (1) p. 484.
11. Shaw, J. F., R. C. Chang, F. F. Wang and Y. J. Wang.
1990. Biotechnol. Bioeng, 35:132.
1990. Biotechnol. Bioeng, 35:132.
12. Hisamatsu, M. and T. Yamada. 1989. J. Ferment.
Bioeng, 67:219.
Bioeng, 67:219.
13. Peleg, K. and C. Rha 1989. J. Rheol., 32:367 14. Tsen, H. Y. and S. Y. Tsai. 1988. J. Ferment.
Technol., 66:198.
Technol., 66:198.
15. Kise, H., A. Nayakawa and H. Noritomi. 1987.
Biotechnol. Lett., 9: 543.
Biotechnol. Lett., 9: 543.
16. Chang, R. C. and J. F. Shaw. 1986. ICSU(International Council of Scientific Unions) Short Reports, Vol 6.
Contemporary Themes in Biochemistry; 4th Federation of Asian Oceanian Biochemists Congress, Singapore, Nov. 30-Dec 5, 1986.
Contemporary Themes in Biochemistry; 4th Federation of Asian Oceanian Biochemists Congress, Singapore, Nov. 30-Dec 5, 1986.
17. Mitsutomi, M., Y. Uchida and A. Ohtakara 1985 J.
Ferment. Technol., 63:326.
Ferment. Technol., 63:326.
18. Hirano, S. and K. Horiuchi. 1989. Int. J. Biol Macromol., 11: 254.
19. Aiba, S. 1989. Int. J. Biol Macromol., 11:252.
20. Wallbanks, K. R., D. H. Molyneux and M. F. Dirie.
1989. Acta Trop (BaselJ, 46:68.
1989. Acta Trop (BaselJ, 46:68.
21. Struszczyk, H. 1987. J. Appl Polym. Sci., 33:181.
22. Zieba, J. and J. Knapczyk. 1988. Acta Pharm. Technol, 34:88.
23. Domszy, J. G., G. A. F. Roberts and F. A. Wood. 1986.
Chitin in Nature and Technology, R. A. A. Muzzarelli, Ch. Jeuniaux and G. W. Godoy, eds., London and New York: Plenum Press, p. 311.
Chitin in Nature and Technology, R. A. A. Muzzarelli, Ch. Jeuniaux and G. W. Godoy, eds., London and New York: Plenum Press, p. 311.
24. Brine, C. J. 1988. Chitin and Chitosan, S. B.
Gudmund, T. Anthonsen and P. Sanford, eds., London and New York: El~evier Appl. Sci., p. 679.
Gudmund, T. Anthonsen and P. Sanford, eds., London and New York: El~evier Appl. Sci., p. 679.
25. Battilotti, U. and U. Barberini. 1988. J. Molec.
Catal, 43:343.
Catal, 43:343.
26. Chevalier, P., D. Roy and A. Morin. 1989. Appl.
Microbiol. Biotechnol., 30:482.
Microbiol. Biotechnol., 30:482.
27. Chibata, I., I. T. Tosa and T. Sato. 1986. J. Mol Catal., 37:1.
28. Dumitriu, S., M. Popa, V. Artenie and F. Dan. 1986.
Reactive Polymers, 4 :237.
Reactive Polymers, 4 :237.
29. Hisamatu. M., T. Yamada 1989. J. Ferment. Bioeng, 67:219.
30. Labeque, R., B. M. Clark, R. S. Less, J. Ferreira, C.
J. Mullon and R. Langer. 1990. "Polymeric Materials Science and Engineering", Proceedings of the ACS
Division of Polymeric Materials Science and Engineering, VoL 63. Washington, DC: ACS Books &
Journals Division, p. 720.
~-- 2l96l92 31. Goosen, M. F. A., G. M. O'Shea, H. F. Gharapetian, S.
Chou and A. M. Sun. 1985. Biotechn. Bioeng., 27:146.
J. Mullon and R. Langer. 1990. "Polymeric Materials Science and Engineering", Proceedings of the ACS
Division of Polymeric Materials Science and Engineering, VoL 63. Washington, DC: ACS Books &
Journals Division, p. 720.
~-- 2l96l92 31. Goosen, M. F. A., G. M. O'Shea, H. F. Gharapetian, S.
Chou and A. M. Sun. 1985. Biotechn. Bioeng., 27:146.
32. Nil~on, K., W. Scheirer, O. Merten, L. Ostberg, E.
Liehl, H. Katinger and K. Mosbach. 1983. Nature, 302:629.
Liehl, H. Katinger and K. Mosbach. 1983. Nature, 302:629.
33. Scheirer, W., K. Nilsson, O. Merten, H. Katinger and K. Mosbach. 1984. Develop. Biol. St~n~rd., 55:155.
34. Ping, Z. and B. D. Allan. 1992. J. Membrane Sci., 6:247.
35. Kienzle-Sterzer, C. A., D. Rodriguez-Sanchez and C.
K. Tha. 1985. Polymer Bull., 13:1.
K. Tha. 1985. Polymer Bull., 13:1.
36. Roberts, G. A. F. and J. G. Domszy. 1982. Int. J.
Biol. Macromol., 4:374.
Biol. Macromol., 4:374.
37. Kim, K. S. and C. K. Rha. 1989. Chitin and Chitosan, I. G. Skjak-Braek, T. Anthonsen and P. Sandford, eds., London and New York: Elsevier Appl. Sci., p.
617.
617.
38. Shioya, T., C. K. Rha and S. Brand. 1989. Chitin and Chitosan, I. G. Skjak-Braek, T. Anthonsen and P.
Sanford, eds., London and New York: Elsevier Appl.
Sci., p. 627.
Sanford, eds., London and New York: Elsevier Appl.
Sci., p. 627.
39. Melia, C. D. 1991. Critical Rev. Therap. Drug Carrier Systems, 8:395.
40. Yoshioka, T., R. Hirano, T. Shioya and M. Kako. 1990.
Biotechnol. Bioeng., 35:66.
'- ' 21~fil92 41. Beldie, C., S. Dumitriu, N. Aelenei, M. Popa, M. I.
Popa and D. Dumitriu. 1989. Biopolymers, 10:622.
Biotechnol. Bioeng., 35:66.
'- ' 21~fil92 41. Beldie, C., S. Dumitriu, N. Aelenei, M. Popa, M. I.
Popa and D. Dumitriu. 1989. Biopolymers, 10:622.
42. Biely, P., D. Mislovicova and R. Toman. 1988. Methods in Enzymology, Vol. 160, W. A. Wood and S T. Kellogg, eds., New York: Academic Press Inc, p. 536.
43. Sarah, G., R. S De la Motte and F. W. Wagner. 1989.
Proteolytic Bnzymes a Practical Approach, R. J.
Beynon and J. S. Bond, eds., Oxford, New York, Tokyo:
IRL Press, p. 25.
Proteolytic Bnzymes a Practical Approach, R. J.
Beynon and J. S. Bond, eds., Oxford, New York, Tokyo:
IRL Press, p. 25.
44. Shaw, J. F., R. C. Chang, F. F. Wang and Y. J. Wang 1990. Biotechnol. Bioeng, 35:132.
45. Uo, M., M. Numata, M. Suzuki, E. Tamiya, I. Karube and A. Makishima. 1992. J. Ceramic Soc. Jpn., 100:430.
46. Wallbanks, K. R., D. H. Molyneux and M. F. Dirie.
1989. Acta Trop (Basel), 46:63.
1989. Acta Trop (Basel), 46:63.
47. Watanabe, A., H. Noritomi, T. Nagashima and H. Kise.
1991. Jpn. J. Polym. Sci. Technol., 48:247.
1991. Jpn. J. Polym. Sci. Technol., 48:247.
48. Simpson, H. D., U. R. Haufler and R. M. Daniel. 1991.
Biochem. J., 277(Pt. 2):413.
Biochem. J., 277(Pt. 2):413.
49. Gianfreda, L. and M. R. Scarfi. 1991. Molec Cell.
Biochem., 100:97.
Biochem., 100:97.
50. Grzywnowicz, K., K. H. Greppin, M. Brzyska and J.
Lobarzewski. 1993. J. Molec Cat., 80:117.
214~192 51. Puls, J., A. Borchm~nn, D. Gottschalk and J. Wiegel.
1988. Methods in Enzymology, Vol. 160, W. A. Wood and S T. Kellogg, eds., New York: Academic Press, Inc., p. 528.
5 52. Skorikova, E.E., G.A. Vikhoreva, R. I . Kaluzhnaya, A. B . Zezin, L . S . Galbraykh, and W.A. Kabanov . 1988.
Polielektrolitnye kompleksy na osnove chitozana, Vysokomol. Soed., 30: 44 - 49.
53. Kikuchi, Y. and N. Kubota. 1985. Active and selective transport of alkali metal ions through a polyelectrolyte complex membrane consisting of glycol chitosan and the sulfate of poly (vinyl alcohol ) .
Bull. Chem. Soc. Jpn., 587: 2121-2115.
54. Chavasit, V. and A. Torres. 1990. Chitosan-Poly (acrylic acid): mechanism of complex formation and potential industrial applications, Biotechnol.
Prog., 6: 2-6.
55. Fukuda, H. and U. Kikuchi. 1978. Polyelectrolyte complexes of chitosan with sodium carboxymethyldextran, Bull. Chem. Soc.lJpn., 51: 1142-1144.
56. Kikuchi, Y. and A. Noda. 1976. Polyelectrolyte complexes of heparin with chitosan, .J. Appl. Polym.
Sci ., 20: 2561-2563.
21461~2 57. Kikuchi, Y. and H. Fukuda. 1974. Polyelectrolyte complexes of sodium dextran sulfate with chitosan, Ma~romol. Chem., 175:3593-3596.
58. Knorr, D. and M. Daly. 1988. Mechanics and diffusional changes observed in multi-layer chitosan/alginate coacervate capsules, Progress Biochem., 48:48-50.
59. Mireles, C. M. Martino, J. Bouzas and J.A. Torres.
1992. Complex formation of chitosan and naturally occuring polyanions, In: Advances in Chitin and Chitosan (C.J.Brine, P.A. Sansford, J.P. Zikakis, Eds), Elsevier Appl. Sci., p. 506.
60. Hirano, S. C. Mizutani, R. Yamaguchi, and D. Miura.
1978. Formation of the polyelectrolyte complexes of some acidic glycosaminoglycans with partially N-acetylated chitosans, Biopolymers, 17:805-810.
61. Fukuda, H. 1980. Polyelectrolyte complexes of chitosan with sodium carboxymethylcellulose, Bull.
Chem. Soc. Jpn., 53:837-840.
62. Tsuchida, E. and K. Abe. 1986. Polyelectrolyte complexes, In: Development in Ionic Polymers (A.D.
Wilson, and H.J. Prosser, Eds). Elsevier Appl. Sci., London, pp. 191-266.
63. Dumitriu, S., P. Magny, D. Montane, P.F. Vidal, and E. Chornet. 1994. Polyionic hydrogels obtained by complexation between xanthan and chitosan: Their properties as supports for enzyme immobilization, J.
Bioactive Compat. Polym., 9: 184-209.
Lobarzewski. 1993. J. Molec Cat., 80:117.
214~192 51. Puls, J., A. Borchm~nn, D. Gottschalk and J. Wiegel.
1988. Methods in Enzymology, Vol. 160, W. A. Wood and S T. Kellogg, eds., New York: Academic Press, Inc., p. 528.
5 52. Skorikova, E.E., G.A. Vikhoreva, R. I . Kaluzhnaya, A. B . Zezin, L . S . Galbraykh, and W.A. Kabanov . 1988.
Polielektrolitnye kompleksy na osnove chitozana, Vysokomol. Soed., 30: 44 - 49.
53. Kikuchi, Y. and N. Kubota. 1985. Active and selective transport of alkali metal ions through a polyelectrolyte complex membrane consisting of glycol chitosan and the sulfate of poly (vinyl alcohol ) .
Bull. Chem. Soc. Jpn., 587: 2121-2115.
54. Chavasit, V. and A. Torres. 1990. Chitosan-Poly (acrylic acid): mechanism of complex formation and potential industrial applications, Biotechnol.
Prog., 6: 2-6.
55. Fukuda, H. and U. Kikuchi. 1978. Polyelectrolyte complexes of chitosan with sodium carboxymethyldextran, Bull. Chem. Soc.lJpn., 51: 1142-1144.
56. Kikuchi, Y. and A. Noda. 1976. Polyelectrolyte complexes of heparin with chitosan, .J. Appl. Polym.
Sci ., 20: 2561-2563.
21461~2 57. Kikuchi, Y. and H. Fukuda. 1974. Polyelectrolyte complexes of sodium dextran sulfate with chitosan, Ma~romol. Chem., 175:3593-3596.
58. Knorr, D. and M. Daly. 1988. Mechanics and diffusional changes observed in multi-layer chitosan/alginate coacervate capsules, Progress Biochem., 48:48-50.
59. Mireles, C. M. Martino, J. Bouzas and J.A. Torres.
1992. Complex formation of chitosan and naturally occuring polyanions, In: Advances in Chitin and Chitosan (C.J.Brine, P.A. Sansford, J.P. Zikakis, Eds), Elsevier Appl. Sci., p. 506.
60. Hirano, S. C. Mizutani, R. Yamaguchi, and D. Miura.
1978. Formation of the polyelectrolyte complexes of some acidic glycosaminoglycans with partially N-acetylated chitosans, Biopolymers, 17:805-810.
61. Fukuda, H. 1980. Polyelectrolyte complexes of chitosan with sodium carboxymethylcellulose, Bull.
Chem. Soc. Jpn., 53:837-840.
62. Tsuchida, E. and K. Abe. 1986. Polyelectrolyte complexes, In: Development in Ionic Polymers (A.D.
Wilson, and H.J. Prosser, Eds). Elsevier Appl. Sci., London, pp. 191-266.
63. Dumitriu, S., P. Magny, D. Montane, P.F. Vidal, and E. Chornet. 1994. Polyionic hydrogels obtained by complexation between xanthan and chitosan: Their properties as supports for enzyme immobilization, J.
Bioactive Compat. Polym., 9: 184-209.
Claims (4)
1. A water insoluble porous hydrogel for use in encapsulation and controlled release of a biologically active substance, which comprises:
-chitosan -xanthan; and -said biologically active substance;
the chitosan and xanthan being present in said hydrogel in proportions ranging from about 24-40% of chitosan and about 60-76% of xanthan.
-chitosan -xanthan; and -said biologically active substance;
the chitosan and xanthan being present in said hydrogel in proportions ranging from about 24-40% of chitosan and about 60-76% of xanthan.
2. A hydrogel as defined in claim 1, wherein said biological substance is selected from the group consisting of prokaryotic cells, eucaryotic cells, proteins and drugs.
3. A hydrogel as defined in claim 2, wherein said drugs are selected from the group consisting of cephalosporin, tetracycline, oxytetracycline, sulfathiazole, metronidazole, chloramphenicol, daunorubicin, ampicillin, penicillin, erythromycin, quinidine, alacacinomycin and mithramycin gentamycin, bleomycin, amthelmycin, enzomycin A, vancomycin, trichomycin, adenomycin, orthomycin, neomycin, kanamycin and sisomycin.
4. Hydrogel as defined in claim 2, wherein said proteins are enzymes selected from the group consisting of xylanase, lipase, hemicellulase, protease and mixtures of xylanase/lipase, xylanase/protease and xylanase/hemicellulase.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002146192A CA2146192C (en) | 1995-04-03 | 1995-04-03 | Polyionic insoluble hydrogels comprising xanthan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002146192A CA2146192C (en) | 1995-04-03 | 1995-04-03 | Polyionic insoluble hydrogels comprising xanthan |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2146192A1 CA2146192A1 (en) | 1996-10-04 |
| CA2146192C true CA2146192C (en) | 1999-04-06 |
Family
ID=4155559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002146192A Expired - Fee Related CA2146192C (en) | 1995-04-03 | 1995-04-03 | Polyionic insoluble hydrogels comprising xanthan |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2146192C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0710578B1 (en) | 2006-04-05 | 2016-11-29 | Woodland Biofuels Inc | Ethanol production method from synthesis gas |
| CN114990100B (en) * | 2022-06-24 | 2024-01-30 | 陕西科技大学 | Lactase microcapsule preparation method and low-lactose liquid goat milk prepared by using lactase microcapsule |
-
1995
- 1995-04-03 CA CA002146192A patent/CA2146192C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2146192A1 (en) | 1996-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5620706A (en) | Polyionic insoluble hydrogels comprising xanthan and chitosan | |
| Dumitriu et al. | Polyionic hydrogels obtained by complexation between xanthan and chitosan: their properties as supports for enzyme immobilization | |
| Peniche et al. | Chitosan: an attractive biocompatible polymer for microencapsulation | |
| Pellá et al. | Chitosan-based hydrogels: From preparation to biomedical applications | |
| Chan et al. | Semisynthesis of a controlled stimuli-responsive alginate hydrogel | |
| US5089272A (en) | Process for producing capsules having a permeability-controllable membrane | |
| Mi et al. | Chitosan–polyelectrolyte complexation for the preparation of gel beads and controlled release of anticancer drug. I. Effect of phosphorous polyelectrolyte complex and enzymatic hydrolysis of polymer | |
| Lin et al. | pH-sensitive polyelectrolyte complex gel microspheres composed of chitosan/sodium tripolyphosphate/dextran sulfate: swelling kinetics and drug delivery properties | |
| Chandy et al. | Evaluation of modified alginate‐chitosan‐polyethylene glycol microcapsules for cell encapsulation | |
| Mi et al. | Chitosan–polyelectrolyte complexation for the preparation of gel beads and controlled release of anticancer drug. II. Effect of pH‐dependent ionic crosslinking or interpolymer complex using tripolyphosphate or polyphosphate as reagent | |
| Yang et al. | pH-sensitive interpenetrating network hydrogels based on chitosan derivatives and alginate for oral drug delivery | |
| Huguet et al. | Calcium-alginate beads coated with polycationic polymers: comparison of chitosan and DEAE-dextran | |
| Yao et al. | Microcapsules/microspheres related to chitosan | |
| Denkbaş et al. | Norfloxacin-loaded chitosan sponges as wound dressing material | |
| AU649533B2 (en) | Method of preparing microspheres | |
| US5902798A (en) | Method of promoting dermal wound healing with chitosan and heparin or heparin sulfate | |
| Yusof et al. | Preparation and characterization of chitin beads as a wound dressing precursor | |
| CN108653741B (en) | A kind of natural sericin microspheres encapsulated by metal-organic coordination polymer and its preparation method and application | |
| WO2000015272A1 (en) | Polymer immobilized living cells and applications thereof | |
| Wang et al. | Preparation, characterization and applications of low-molecular-weight alginate–oligochitosan nanocapsules | |
| Goycoolea et al. | Effect of chemical crosslinking on the swelling and shrinking properties of thermal and pH‐responsive chitosan hydrogels | |
| Hu et al. | Preparation and characterization of composite hydrogel beads based on sodium alginate | |
| EP0941068B1 (en) | Controlled release microspheres | |
| CN119074638B (en) | A polypeptide hydrogel based on oxidized Ganoderma lucidum polysaccharide and its application | |
| KR101929293B1 (en) | Dual ionic crosslinked interpenetrating network of alginate-cellulose beads and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |